Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial
Gianluigi Savarese1, Alicia Uijl1,2,3, Lars H. Lund1, Stefan D. Anker4, Folkert W. Asselbergs2,3, David Fitchett5, Silvio E. Inzucchi6, Stefan Koudstaal2,3, Anne Pernille Ofstad7, Benedikt Schrage1, Ola Vedin8, Christoph Wanner9, Faiez Zannad10, Isabella Zwiener11, Javed Butler12
1Division of Cardiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden
2Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
3Institute of Cardiovascular Science, Faculty of Population Health Sciences, Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom
4Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin, Germany
5St Michael's Hospital, Division of Cardiology, University of Toronto, ON, Canada
6Yale University School of Medicine, New Haven, CT, USA
7Boehringer Ingelheim Norway KS, Asker, Norway
8Boehringer Ingelheim AB, Stockholm, Sweden
9Würzburg University Clinic, Würzburg, Germany
10Institut Lorrain du Coeur et des Vaisseaux, Nancy, France
11Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
12Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA
Thông tin
Thông tin xuất bản
Journal of Cardiac Failure
Tập 27
888-895
Thông tin tác giả